Physician profile
Firas El Chaer
NPI 1659624856
$104,786.68
in general payments reported to CMS, 2019-2025
22 companies · $89K in 2025
The $89K reported for 2025 was more than what 98% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2021: $72.81 · 2022: $1,038 · 2023: $11K · 2024: $2,919 · 2025: $89K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $53K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Travel and Lodging: $9,655 · Education: $8,955 · Food and Beverage: $3,154 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $53,339.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,625.00 |
| Travel and Lodging | $9,655.31 |
| Education | $8,954.75 |
| Food and Beverage | $3,154.03 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,725.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Syndax Pharmaceuticals, INC. | $34,607.79 | 2025 | Revuforj |
| Pharmaessentia USA Corporation | $24,507.43 | 2024-2025 | Besremi |
| Sumitomo Pharma America, INC. | $11,923.26 | 2024-2025 | |
| Amgen INC. | $7,993.45 | 2021-2025 | Blincyto, Blincyto |
| Abbvie INC. | $6,217.40 | 2023-2025 | |
| Glaxosmithkline, LLC. | $4,750.00 | 2025 | Ojjaara |
| Novartis Pharmaceuticals Corporation | $3,088.71 | 2023-2025 | |
| Taiho Oncology, INC. | $2,607.31 | 2024-2025 | |
| Morphosys, US INC. | $2,597.55 | 2023 | |
| Merck Sharp & Dohme LLC | $2,240.00 | 2025 | |
| Cti Biopharma Corp. | $1,725.00 | 2023 | Vonjo |
| Celgene Corporation | $1,045.92 | 2022-2023 | Reblozyl |
| Daiichi Sankyo INC. | $650.00 | 2025 | Vanflyta |
| Genzyme Corporation | $141.36 | 2025 | |
| Pfizer INC. | $126.82 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $120.06 | 2025 | |
| Exelixis INC. | $112.37 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $109.84 | 2019 | |
| Sanofi US Services INC. | $83.20 | 2025 | |
| Geron Corporation | $70.49 | 2024-2025 | Rytelo |
| E.R. Squibb & Sons, L.L.C. | $44.30 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $24.42 | 2023 | Imbruvica |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Firas El Chaer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.